PDF(Pubmed)
Abstract：
UNASSIGNED: Venous thromboembolism (VTE) is a serious complication in non-small cell lung cancer (NSCLC) patients. The use of thromboprophylactic therapy is subject to an accurate assessment of the VTE risk depending on patients, tumor characteristics and type of systemic antineoplastic treatments. However, little is known concerning the risk of VTE in patients suffering from an advanced NSCLC treated with first-line chemo-immunotherapy and the impact of tumor biomarkers such as PD-L1 expression.
UNASSIGNED: We performed a retrospective, observational, single-centre study in a cohort of advanced NSCLC patients treated with first-line chemo-immunotherapy. The primary endpoint was the incidence of VTE. Secondary endpoints were the cumulative incidence of VTE, the impact of PD-L1 on VTE occurrence, overall survival, the rate of VTE recurrence under anticoagulant treatment and the rate of bleeding complications.
UNASSIGNED: 109 patients were included, of whom 21 (19.3%) presented a VTE event during a median follow-up of 13 months. VTE incidence at 3, 6 and 12 months was 12.1%, 15.1% and 17.5% respectively. 61% were pulmonary embolisms, 9.5% were isolated deep vein thrombosis and 14.3% were central venous catheter-related thrombosis. Our study did not show a significant impact of PD-L1 on VTE occurrence. Overall survival at 6, 12 and 24 months was 81.9%, 74.4% and 70.3% respectively. Four patients developed a recurrent VTE under anticoagulation therapy 3 to 5 months after the first VTE event. One patient suffered from a major bleeding complication while under anticoagulation therapy, leading to death.
UNASSIGNED: VTE is a common complication in advanced NSCLC patients treated with concomitant chemo-immunotherapy. In our study, 19.3% of patients developed a VTE during a median follow-up of 13 months. PD-L1 did not appear to be associated with VTE occurrence. We recorded high VTE recurrence rates despite anticoagulant treatment. Further investigations are needed to determine if high PD-L1 expression is associated with VTE.
UNASSIGNED: We performed a retrospective, observational, single-centre study in a cohort of advanced NSCLC patients treated with first-line chemo-immunotherapy. The primary endpoint was the incidence of VTE. Secondary endpoints were the cumulative incidence of VTE, the impact of PD-L1 on VTE occurrence, overall survival, the rate of VTE recurrence under anticoagulant treatment and the rate of bleeding complications.
UNASSIGNED: 109 patients were included, of whom 21 (19.3%) presented a VTE event during a median follow-up of 13 months. VTE incidence at 3, 6 and 12 months was 12.1%, 15.1% and 17.5% respectively. 61% were pulmonary embolisms, 9.5% were isolated deep vein thrombosis and 14.3% were central venous catheter-related thrombosis. Our study did not show a significant impact of PD-L1 on VTE occurrence. Overall survival at 6, 12 and 24 months was 81.9%, 74.4% and 70.3% respectively. Four patients developed a recurrent VTE under anticoagulation therapy 3 to 5 months after the first VTE event. One patient suffered from a major bleeding complication while under anticoagulation therapy, leading to death.
UNASSIGNED: VTE is a common complication in advanced NSCLC patients treated with concomitant chemo-immunotherapy. In our study, 19.3% of patients developed a VTE during a median follow-up of 13 months. PD-L1 did not appear to be associated with VTE occurrence. We recorded high VTE recurrence rates despite anticoagulant treatment. Further investigations are needed to determine if high PD-L1 expression is associated with VTE.
摘要：
■静脉血栓栓塞症（VTE）是非小细胞肺癌（NSCLC）患者的严重并发症。血栓预防治疗的使用取决于患者对VTE风险的准确评估，肿瘤特征和全身抗肿瘤治疗的类型。然而,对于接受一线化学免疫疗法治疗的晚期NSCLC患者的VTE风险以及PD-L1表达等肿瘤生物标志物的影响,人们知之甚少.
■我们进行了回顾性研究，观察,在接受一线化学免疫疗法治疗的晚期NSCLC患者队列中进行的单中心研究。主要终点是VTE的发生率。次要终点是VTE的累积发生率，PD-L1对VTE发生的影响，总生存率,抗凝治疗下VTE复发率和出血并发症发生率。
■109名患者被纳入，其中21人(19.3%)在13个月的中位随访期间出现VTE事件.3、6和12个月的VTE发生率为12.1%，分别为15.1%和17.5%。61%为肺栓塞,9．5％为孤立性深静脉血栓形成，14．3％为中心静脉导管相关性血栓形成。我们的研究未显示PD-L1对VTE发生的显著影响。6、12和24个月的总生存率为81.9%，分别为74.4%和70.3%。4例患者在首次VTE事件后3至5个月的抗凝治疗下出现复发性VTE。一名患者在接受抗凝治疗时出现严重出血并发症，导致死亡。
■VTE是合并化疗免疫治疗的晚期NSCLC患者的常见并发症。在我们的研究中,19.3%的患者在13个月的中位随访期间发生VTE。PD-L1似乎与VTE的发生无关。尽管抗凝治疗，我们记录的VTE复发率很高。需要进一步的研究来确定高PD-L1表达是否与VTE相关。
■我们进行了回顾性研究，观察,在接受一线化学免疫疗法治疗的晚期NSCLC患者队列中进行的单中心研究。主要终点是VTE的发生率。次要终点是VTE的累积发生率，PD-L1对VTE发生的影响，总生存率,抗凝治疗下VTE复发率和出血并发症发生率。
■109名患者被纳入，其中21人(19.3%)在13个月的中位随访期间出现VTE事件.3、6和12个月的VTE发生率为12.1%，分别为15.1%和17.5%。61%为肺栓塞,9．5％为孤立性深静脉血栓形成，14．3％为中心静脉导管相关性血栓形成。我们的研究未显示PD-L1对VTE发生的显著影响。6、12和24个月的总生存率为81.9%，分别为74.4%和70.3%。4例患者在首次VTE事件后3至5个月的抗凝治疗下出现复发性VTE。一名患者在接受抗凝治疗时出现严重出血并发症，导致死亡。
■VTE是合并化疗免疫治疗的晚期NSCLC患者的常见并发症。在我们的研究中,19.3%的患者在13个月的中位随访期间发生VTE。PD-L1似乎与VTE的发生无关。尽管抗凝治疗，我们记录的VTE复发率很高。需要进一步的研究来确定高PD-L1表达是否与VTE相关。
